… H. Marshall, PhD, Novartis’ president of biomedical research [Novartis]“This new agreement … certain of those programs with Novartis, leveraging their recognized development … extension from payments associated with Novartis collaboration announced Sep[temper] …

… each for Bristol Myers Squibb, Novartis, UCB, Boehringer Ingelheim and Phathom … . A scolding for one of Novartis’ Kesimpta ads, for example, takes …

… company’s pipeline. Novartis has expanded its collaboration … and commercialised by Novartis. This is Novartis’ second agreement with … extend our relationship with Novartis beyond our previously announced … of Biomedical Research at Novartis noted that the deal …

… revoked the patent on Novartis’ cardiac drug Entresto, sold … , opposed the patent on Novartis’ heart-failure drug Vymada. … The Indian Pharmaceutical Alliance opposed Novartis’ patent on Vymada. File … in court. “The patentee (Novartis) abstained from the hearing. …

… . Lastly, in biopharma business news, Novartis has signed a $5.7 … autoimmune and inflammatory diseases, expanding Novartis’s pipeline in one of …

… the US$5.7bn deal, Novartis AG secures exclusive rights to … announcement of the collaboration with Novartis, trading volume in Monte Rosa … Rosa Therapeutics’ second deal with Novartis AG, following a US$2 …

… has revoked the patent on Novartis’ blockbuster therapy Vymada, citing … and heart failure. For Novartis, the drug is a … prioritised access to affordable medicines. Novartis’ patent, filed in 2007 … Legal observers noted that Novartis abstained from the final …

… has revoked the patent on Novartis' cardiac blockbuster drug … provision - under which Novartis also lost the patent … A questionnaire mailed to Novartis failed to elicit a response … 2023. "The patentee (Novartis) abstained from the hearing. Therefore …

… chapter for the high-profile Novartis scandal, two former protected witnesses … Marangeli, the former secretary of Novartis executive Konstantinos Frouzis, were sentenced …